Clinical Trial: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Intravitreal Tissue Plasminogen Activator (tPA) And Perfluoropropane (C3F8) for the Treatment of Neovascular Age-related Macular Degeneration With Associated Submacular Haemorrhage (TAPAS): a Multi-ce

Brief Summary:

This study will recruit patients who have recently had a submacular haemorrhage (bleed under the part of the retina responsible for detailed vision), as a complication of wet age-related macular degeneration (wet AMD). Wet AMD is a very common disease where abnormal blood vessels form under the retina and leak, causing a significant reduction in vision.

The study will investigate treatment of the bleed with various combinations of the two drugs: tissue plasminogen activator (tPA) - designed to dissolve the blood clot; and perfluoropropane (C3F8) - designed to shift the blood clot away from the central part of the retina (the macula). tPA is a commonly used 'clot-buster' drug for the treatment of stroke. C3F8 is a gas commonly used in eye surgery. Patients recruited will be divided into four groups: control group that receive none of the above drugs; one group that receives only tPA; one group that receives only C3F8; and one group that receives both.

All patients will receive the current gold standard treatment for wet AMD, ranibizumab (Lucentis®).

The aim of the study is to improve vision in a condition, which left untreated, would cause severe visual loss.


Detailed Summary:

Age-related macular degeneration (AMD) is the commonest cause of blindness worldwide. Its prevalence increases with age, being relatively rare under 60 years and reaching its peak incidence in those older than 80 years. AMD principally affects central vision, which is responsible for the ability to see fine detail and the disease rapidly destroys the ability to read normal print, recognise faces, drive, and watch television. It can therefore have a profound effect on quality of life.

There are two main forms of AMD; the dry form, in which there is slow degeneration of the cells responsible for sight, resulting in gradual visual loss; and the wet form (neovascular), which occurs when abnormal blood vessels (choroidal neovascularisation) grow under the retina, the part of the eye which is responsible for sensing light, like the film of a camera. These new blood vessels have weak walls leading to leakage of fluid (oedema), and sometimes significant amounts of bleeding (submacular haemorrhage - SMH). These rapidly lead to central visual distortion and blurring. Although the dry form is commoner, the wet form more commonly results in profound central visual loss and is responsible for the majority of cases that ultimately require blind registration.

The current best treatment ('gold-standard') for wet AMD is the drug ranibizumab (Lucentis®), which aims to shrink and destroy the abnormal blood vessels responsible for the visual symptoms. In several trials ranibizumab has been shown to improve vision in patients with wet AMD.

It is not uncommon for patients with wet AMD to develop SMH, which when it occurs, significantly reduces the patient's visual prognosis. SMH is thought to have a number of toxic consequences on the retinal function.

Same as current

Current Secondary Outcome:

  • Mean ETDRS visual acuity [ Time Frame: 1 and 12 months ]
  • Percentage patients 15 letters or greater improvement in ETDRS visual acuity [ Time Frame: 12 months ]
  • Percentage patients 0 letters or greater improvement in ETDRS visual acuity [ Time Frame: 12 months ]
  • Percentage patients 15 letters or greater loss in ETDRS visual acuity [ Time Frame: 12 months ]
  • Mean total area of macular haemorrhage on colour fundus photography [ Time Frame: 1, 3 and 6 months ]
  • Greatest linear dimension of macular haemorrhage on colour fundus photography [ Time Frame: 1, 3 and 6 months ]
  • Presence of subfoveal blood on colour fundus photography [ Time Frame: 1 month ]


Original Secondary Outcome: Same as current

Information By: King's College Hospital NHS Trust

Dates:
Date Received: April 16, 2013
Date Started: September 2013
Date Completion: November 2017
Last Updated: January 22, 2016
Last Verified: January 2016